Low-dose-rate brachytherapy remains feasible for prostate cancer patients with median lobe hyperplasia. 

Key clinical point: Median lobe hyperplasia did not interfere with low-dose-rate brachytherapy, but seed migration and degree of cold spots was higher in patients with severe MLH.

Major finding: Migration of iodine-125 seeds occurred in 10 (31.5%) of 32 prostate cancer patients with MLH and 61 (31.6%) of 193 prostate cancer patients without MLH.

Study details: The data come from an analysis of 32 prostate cancer patients with median lobe hyperplasia (MLH) and 193 without MLH; all patients were treated with loose iodine-125 seeds. MLH patients were classified as mild (< 10 mm) or severe (≥ 10 mm) based on the distance between the posterior transitional zone and the prostatic tissue protruding into the bladder.

,

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Muraki K et al. J Contemp Brachytherapy. 2021 Jun 13. doi: 10.5114/jcb.2021.105944.